Arrowhead Pharmaceuticals' SWOT analysis: stock poised for potential breakthrough
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...
RBC Capital Remains a Buy on Arrowhead Pharmaceuticals (ARWR)
In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives “Buy” Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research ...
ETF Daily News3d
Arrowhead Pharmaceuticals (ARWR) to Release Earnings on Tuesday
Sanford C. Bernstein decreased their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a report on Friday, November 29th.
Investing23d
Arrowhead Pharmaceuticals' chief sells $648,824 in stock
Hamilton James C, Chief of Discovery/Trans Medicine at Arrowhead Pharmaceuticals ... The transaction comes as the stock has declined over 50% in the past year, with InvestingPro data showing ...
Nasdaq5d
Arrowhead Pharmaceuticals, Inc. Common Stock (ARWR) Short Interest
Short interest and days to cover can be used to indicate market sentiment and gauge the stock market in an investor’s analysis. Please note: If days to cover is between 0 and 1, it is rounded up ...
Business Insider28d
Arrowhead Pharmaceuticals: Strong Growth Potential Backed by siRNA Therapeutics and Financial Stability
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR ... smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...